ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.344,88
0,30%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7346
0,00%
Bitcoin
84.714,01
1,04%
Brent Oil
71,775
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Supernus Pharmaceuticals Inc (SUPN)

  7. Supernus Pharmaceuticals Inc (SUPN) Notícias

SUPN

Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SUPN
DataHoraFonteTítuloCódigoCompanhia
11/03/202517:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
04/03/202518:30GlobeNewswire Inc.Supernus to Participate in Two Upcoming Investor ConferencesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/02/202510:30GlobeNewswire Inc.Supernus to Participate in the TD Cowen 45th Annual Health Care ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
25/02/202518:13Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SUPNSupernus Pharmaceuticals Inc
25/02/202518:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SUPNSupernus Pharmaceuticals Inc
25/02/202518:01GlobeNewswire Inc.Supernus Announces Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/02/202519:00Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SUPNSupernus Pharmaceuticals Inc
18/02/202518:25GlobeNewswire Inc.Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant DepressionNASDAQ:SUPNSupernus Pharmaceuticals Inc
14/02/202519:20Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
11/02/202518:30GlobeNewswire Inc.Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
05/02/202518:33Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
04/02/202511:00GlobeNewswire Inc.Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s DiseaseNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/01/202518:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SUPNSupernus Pharmaceuticals Inc
27/01/202510:00GlobeNewswire Inc.Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding WomenNASDAQ:SUPNSupernus Pharmaceuticals Inc
16/12/202418:30GlobeNewswire Inc.Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in CanadaNASDAQ:SUPNSupernus Pharmaceuticals Inc
26/11/202419:00GlobeNewswire Inc.Supernus to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
14/11/202419:14Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SUPNSupernus Pharmaceuticals Inc
13/11/202418:30GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202418:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SUPNSupernus Pharmaceuticals Inc
04/11/202418:05GlobeNewswire Inc.Supernus Announces Third Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
31/10/202417:10GlobeNewswire Inc.Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024NASDAQ:SUPNSupernus Pharmaceuticals Inc
21/10/202417:25GlobeNewswire Inc.Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
18/10/202407:09IH Market NewsiPhone 16 Sales in China Up 20%; Sobr Safe Jumps 108% Pre-Market; Netflix and Intuitive Surgical Beat EstimatesNASDAQ:SUPNSupernus Pharmaceuticals Inc
17/10/202417:05GlobeNewswire Inc.Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive DisorderNASDAQ:SUPNSupernus Pharmaceuticals Inc
10/10/202418:12GlobeNewswire Inc.Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive DisorderNASDAQ:SUPNSupernus Pharmaceuticals Inc
24/09/202408:30GlobeNewswire Inc.Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and QelbreeNASDAQ:SUPNSupernus Pharmaceuticals Inc
19/09/202417:30GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry SummitNASDAQ:SUPNSupernus Pharmaceuticals Inc
28/08/202417:15GlobeNewswire Inc.Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare ConferenceNASDAQ:SUPNSupernus Pharmaceuticals Inc
19/08/202408:00GlobeNewswire Inc.Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDANASDAQ:SUPNSupernus Pharmaceuticals Inc
06/08/202417:06GlobeNewswire Inc.Supernus Announces Second Quarter 2024 Financial ResultsNASDAQ:SUPNSupernus Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SUPN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios